Published in Hepatitis Weekly, April 19th, 2004
According to recent research from Egypt, "hepatitis C virus (HCV) infection continues to be an emerging global health concern. With the advent of additional treatment protocols, a simple and reliable assay for changes in HCV load may permit more frequent patient assessment and tailoring of the therapeutic regimen. Recently, we have developed a highly sensitive and specific enzyme immunoassay (EIA) for the detection of an HCV-nonstructural 4 (NS4) antigen in serum."
"Here, we evaluated the efficacy of the developed assay in monitoring the virologic responses to pegylated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.